The 2-hydroxy-nevirapine metabolite as a candidate for boosting apolipoprotein A1 and for modulating anti-HDL antibodiesPHARMACOLOGICAL RESEARCHIF10.52021-03-012PREAI
Singularities of nevirapine metabolism: from sex-dependent differences to idiosyncratic toxicity奈韦拉平代谢的奇异性: 从性别依赖性差异到特质毒性DRUG METABOLISM REVIEWSIF3.82019-03-299PRE
ANTI-HISTONE ANTIBODIES IN HIV-INFECTED PATIENTS ON NEVIRAPINE-CONTAINING ANTIRETROVIRAL THERAPYCLINICAL THERAPEUTICSIF3.62015-08-011OAAI
Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactionsJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62013-09-1930OA
Evidence for nevirapine bioactivation in man: Searching for the first step in the mechanism of nevirapine toxicityTOXICOLOGYIF4.62012-11-0147OAAI
Long-term maraviroc use as salvage therapy in HIV-2 infectionJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62012-06-2212OA
Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patientsBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32009-11-2712OAAI
Efavirenz concentrations in HIV-infected patients with and without viral hepatitisBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32008-09-1117OAAI
Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patientsBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32006-03-2729OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向